CLDI News & Events

Calidi Biotherapeutics presented new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer, SITC, Annual Meeting. "Our latest data demonstrate that in our syngeneic murine models, our RedTail platform is protected from immune clearance after systemic administration and can find and specifically replicate in tumor cells at metastatic sites," said Antonio Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations at Calidi. "The data also demonstrate that the platform can effectively express genetic medicines at the tumor site in concentrations that are similar to what is achievable with localized dosing while avoiding systemic exposure."

Calidi Biotherapeutics announced the presentation of new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer, SITC, Annual Meeting. Calidi is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug, IND, application by the end of 2026. The company is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.

Calidi Biotherapeutics announced the formation of its Scientific Advisory Board, SAB. The SAB will work with Calidi to further develop its RedTail platform and advance CLD-401 into the clinic. RedTail is Calidi's approach to genetic medicines that utilizes an enveloped form of vaccinia virus genetically engineered to overexpress CD55 and avoid immune clearance.

Calidi Biotherapeutics announced the pricing of an underwritten public offering for gross proceeds of $6M prior to deducting underwriting commissions and offering expenses. The offering is comprised of 1,472,764 common stock units with each unit consisting of one share of common stock and one Series I warrant to purchase one share of common stock and 1,528,000 pre-funded warrant units consisting of one pre-funded warrant to purchase one share of common stock and one Series I warrant to purchase one share of common stock. The price per Common Stock Unit is $2.00 and the price per Pre-Funded Unit is $1.999. The Series I warrant will have an exercise price of $2.00 per share, will be exercisable upon issuance, and have a term expiring five years from issuance. The warrants issued in this offering are fixed priced and do not contain any variable price features. Ladenburg Thalmann & Co. is acting as sole book-running manager for the offering. Laidlaw & Company is acting as a co-manager for the offering. In addition, Calidi has granted the underwriters a 45-day option to purchase up to an additional 450,000 shares of common stock and/or warrants, at the public offering price, less underwriting discounts and commissions. This offering is expected to close on or about August 21, 2025, subject to the satisfaction of customary closing conditions.